

# KEY PRODUCTS DRIVING EXCEPTIONAL PERFORMANCE

## SALES WORLDWIDE

**\$7.5**  
billion

**+7.1%**<sup>1</sup>  
on organic basis

## STRONG PERFORMANCE ACROSS ALL CORE BUSINESSES<sup>2</sup>

SALES ON ORGANIC BASIS\*



**+9.5%**

MEDICAL DEVICES



**+6.7%**

NUTRITION



**+4.4%**

DIAGNOSTICS



**+5.4%**

ESTABLISHED PHARMACEUTICALS

## FULL-YEAR 2019 GUIDANCE<sup>3</sup>

**\$3.15 to \$3.25**

ADJUSTED DILUTED EPS

MIDPOINT REFLECTS DOUBLE-DIGIT GROWTH

## NEW PRODUCT ADVANCEMENTS

### U.S. APPROVALS

#### Amplatzer Piccolo™ Occluder

A pea-sized device that can mend the hearts of premature infants

#### Mitraclip™

**Expanded Use** The first transcatheter device approved in the U.S. to treat advanced heart failure patients with significant secondary mitral regurgitation

#### TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™

A new catheter to help physicians treat irregular heartbeats

### EUROPEAN APPROVALS<sup>4</sup>

#### Alinity™ m

The latest molecular testing platform for infectious disease

#### Determine™ HBsAg 2

The world's most sensitive rapid diagnostic test for the detection of hepatitis B<sup>5,6,7</sup>



### DIABETES CARE: TAKING CONNECTED DATA TO THE NEXT LEVEL

**Abbott and Novo Nordisk partner** to enable insulin data sharing between connected insulin pens and FreeStyle® LibreLink and LibreView

Real-world evidence from nearly half a million FreeStyle® Libre system users shows higher rates of scanning **improves control of diabetes**<sup>8</sup>

### REINVENTING THE LABORATORY

- ▶ Alinity™ ci-series, our most advanced diagnostic testing technology, is being used by **one of the largest reference labs** in the U.S.

Abbott and the Japanese Red Cross Society enter **long-term partnership** for blood screening



\*Organic sales growth excludes the prior year first-quarter results for a non-core business within U.S. Adult Nutrition, which was discontinued during the third quarter of 2018; and excludes the impact of foreign exchange. For full financial data and reconciliation of non-GAAP measures, please see our press release dated April 17, 2019, available at [www.abbott.com](http://www.abbott.com).

1. On a GAAP basis, Abbott sales increased 2.0%.

2. On a GAAP basis, Medical Devices sales increased 5.5%; Nutrition sales increased 2.0%; Diagnostics sales increased 0.2%; and Established Pharmaceuticals sales decreased 4.9%.

3. Adjusted diluted EPS excludes specified items. Full-year 2019 GAAP guidance of \$1.95 to \$2.05.

4. Alinity m is in development and not commercially available in the United States for diagnostic use. Determine™ HBsAg 2 is not commercially available in the United States.

5. Amini A, Varsaneux O, Kelly H et al. Diagnostic accuracy of tests to detect hepatitis B surface antigen: a systematic review of the literature and meta-analysis. BMC Infect Dis 2017; 17(Suppl 1):698-716;

6. World Health Organization. WHO performance evaluation acceptance criteria for HBsAg *In vitro* diagnostics in the context of WHO prequalification. Available at: [http://www.who.int/diagnostics\\_laboratory/evaluations/hepb/161125\\_who\\_performance\\_criteria\\_hbsag\\_ivd.pdf?ua=1](http://www.who.int/diagnostics_laboratory/evaluations/hepb/161125_who_performance_criteria_hbsag_ivd.pdf?ua=1). Accessed 29 January 2019;

7. Downing RG., Forssten C., Kabbale P., Newton R., Robins T., Tamanoue Y. (2019, February). Determine™ HBsAg 2: A novel rapid test for the detection of hepatitis B virus infection. Poster session presented at: 28th Conference of Asian Pacific Association for the Study of the Liver; 2019 February 20-24; Manila, Philippines; based on package inserts or other company-produced material in public domain.

8. Lang, SR Jangam et al, Expanded Real-world Use Confirms Strong Association between Frequency of Flash Glucose Monitoring and Glucose Control. Presented at the 12th Advanced Technologies & Treatments for Diabetes (ATTD) in Berlin, Germany. <https://cmoffice.kenes.com/cmsearchableprogrammeV15/conferencemanager/programme/personid/anonymous/atttd19/normal/b833d15f547f3cf698a5e922754684fa334885ed#/abstractdetails/0000258110>

### FORWARD-LOOKING STATEMENTS

Some statements in this communication may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors," to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended December 31, 2018, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.